Currently, the diagnosis of AD is reliant on detecting decreased Aβ42 and elevated tau levels in the CSF,4 cerebral glucose hypometabolism, and increased Aβ and tau deposition on PET images.5 This evidence concerns the gene MAPT and Alzheimer disease.